Anti-Virulence Strategies Against Gram-Negative Pathogens

The rise of antimicrobial resistance among Gram-negative pathogens has prompted a paradigm shift from bactericidal approaches towards neutralising disease-causing mechanisms without impairing bacterial viability. Anti-virulence strategies harness molecular decoys, enzyme inhibitors and secretion-system antagonists to disarm pathogens such as Pseudomonas aeruginosa, Escherichia coli and Yersinia spp. By targeting structures essential for host colonisation and immune evasion—including pili, elastases and type III secretion systems (T3SS)—these approaches minimise selective pressures for resistance and preserve the beneficial microbiota. Progress in structure-based design and high-throughput screening has yielded small molecules that block toxin delivery or adhesion, while glycomimetic compounds act as competitive ligands for bacterial adhesins. Interventions combining antivirulence agents with conventional antibiotics show promise in enhancing treatment efficacy and reducing inflammation. Collectively, these strategies represent a multifaceted arsenal for tackling drug-resistant infections and underscore the potential for precision therapies in the post-antibiotic era.

Research from Nature Portfolio

Recent studies have explored plant-derived resveratrol dimers as inhibitors of the T3SS in Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Structural analyses revealed that benzofuran-core compounds impede effector protein secretion, reducing virulence in cell-based assays. Novel screening methods employing fluorescent reporters under T3SS promoters enabled efficient identification of active analogues. This work elucidates structure–activity relationships and underscores the feasibility of rational design of antivirulence agents against Gram-negative pathogens.

Anti-Virulence Strategies Against Gram-Negative Pathogens publication trend

The graph below shows the total number of articles in anti-virulence strategies against gram-negative pathogens across all publications each year (not limited to Nature Index journals).

Technical terms

Anti-virulence strategy: A therapeutic approach that neutralises or inhibits pathogenic mechanisms rather than killing bacteria, thereby reducing selection pressure for resistance.

Type III secretion system (T3SS): A specialised apparatus used by Gram-negative bacteria to inject effector proteins into host cells, facilitating colonisation and immune evasion.

Virulence factor: A molecular determinant produced by a pathogen that enables host tissue damage, immune modulation or colonisation.

Glycomimetic: A synthetic compound designed to mimic host-derived sugar receptors, serving as a decoy to block bacterial adhesion.

Benzofuran core: A chemical scaffold consisting of fused benzene and furan rings, utilised in the design of T3SS inhibitory resveratrol dimers.

References

1. Disarming Gram-Negative Bacteria in the Fight Against Antimicrobial Resistance. ACS Central Science (2023).
2. Exploring resveratrol dimers as virulence blocking agents – Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Scientific Reports (2020).
3. Attenuation of Pseudomonas aeruginosa infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis. Virulence (2020).
4. Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4‐disubstituted‐4H‐[1,3,4]‐thiadiazine‐5‐ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice. BioMed Research International (2018).
5. Approaches to the Structure-Based Design of Antivirulence Drugs: Therapeutics for the Post-Antibiotic Era. Molecules (2019).
6. Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment. Journal of Theoretical Biology (2015).
7. Precision antimicrobial therapeutics: the path of least resistance?. npj Biofilms and Microbiomes (2018).